Show simple item record

dc.contributor.authorButcher, Lee
dc.contributor.authorCarnicero, Jose Antonio
dc.contributor.authorPeres, Karine
dc.contributor.authorColpo, Marco
dc.contributor.authorGomez-Cabrero, David
dc.contributor.authorDartigues, Jean-François
dc.contributor.authorBandinelli, Stefania
dc.contributor.authorGarcia-Garcia, Francisco Jose
dc.contributor.authorManas, Leocadio Rodriguez
dc.contributor.authorErusalimsky, Jorge
dc.date.accessioned2020-10-16T11:11:42Z
dc.date.available2020-10-16T11:11:42Z
dc.date.issued2020
dc.identifier.issn0304-324X
dc.identifier.issn1423-0003 (online)
dc.identifier.urihttp://hdl.handle.net/10369/11172
dc.descriptionArticle accepted for publication in Gerontologyen_US
dc.description.abstractIntroduction: The evidence that blood levels of the soluble receptor for advanced glycation end products (sRAGE) predict mortality in people with cardiovascular diseases (CVD) is inconsistent. To clarify this matter, we investigated if frailty status influences this association. Methods: We analysed data of 1016 individuals (median age, 75 years) from three population-based European cohorts, enrolled in the FRAILOMIC project. Participants were stratified by history of CVD and frailty status. Mortality was recorded during 8 years of follow-up. Results: In adjusted Cox regression models baseline serum sRAGE was positively associated with an increased risk of mortality in participants with CVD (HR 1.64, 95%CI 1.09-2.49, P=0.019), but not in non-CVD. Within the CVD group, the risk of death was markedly enhanced in the frail subgroup (CVD-F, HR 1.97, 95%CI 1.18- 3.29, P=0.009), compared to the non-frail subgroup (CVD-NF, HR 1.50, 95%CI 0.71- 3.15, P=0.287). Kaplan-Meier analysis showed that the median survival time of CVDF with high sRAGE (>1554 pg/mL) was 2.9 years shorter than that of CVD-F with low sRAGE, whereas no survival difference was seen for CVD-NF. Area under the ROC curve analysis demonstrated that for CVD-F, addition of sRAGE to the prediction model increased its prognostic value. Conclusions: Frailty status influences the relationship between sRAGE and mortality in older adults with CVD. sRAGE could be used as a prognostic marker of mortality for these individuals, particularly if they are also frail.en_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofseriesGerontology;
dc.subjectcardiovascular diseaseen_US
dc.subjectfrailtyen_US
dc.subjectmortalityen_US
dc.subjectprognosticen_US
dc.titleHigher sRAGE levels predict mortality in frail older adults with cardiovascular diseaseen_US
dc.typeArticleen_US
dcterms.dateAccepted2020-10-14
rioxxterms.funderCardiff Metropolitan Universityen_US
rioxxterms.identifier.projectCardiff Metropolian (Internal)en_US
rioxxterms.versionAMen_US
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
rioxxterms.freetoread.startdate2100-01-01
rioxxterms.funder.project37baf166-7129-4cd4-b6a1-507454d1372een_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record